Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
CH

OTC · CHGCY

Chugai Pharmaceutical Co., Ltd.

Healthcare · Drug Manufacturers - General

$19.16

Up+$0.00 (+0.00%)

Updated Oct 11, 2026, 4:08 PM

SID Score

6.1/10

Composite research score

Smart Money

46/100

Neutral

Market cap
89.03B
P/E ratio
35.25
Dividend yield
3.20%
52-week range
— – —
Volume
16.75K
Avg. volume
145.36K

Price performance · CHGCY

CHGCY price history

1M range · 0 trading sessions · Daily adjusted prices

CHGCY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CHGCY news

The latest Smart Investors Daily articles mentioning CHGCY.

Stock researchCompany · Overview

CHGCY research

Overview

Company profile and research snapshot.

Company profile

CHUGAI PHARM UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
—
Implied upside
—
Analysts
20
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 5, 2026

Will Regaining Emugrobart Rights and Refocusing on SMA Change Chugai Pharmaceutical's (TSE:4519) Narrative

In September 2026, Chugai Pharmaceutical reported that Roche will discontinue development of the anti-latent myostatin antibody emugrobart for obesity and return all rights, after interim Phase II data suggested clinically meaningful weight loss targets were unlikely to be met despite a favorable safety profile. With those rights now back in-house, Chugai is preparing to restart development of emugrobart for spinal muscular atrophy and is exploring out-licensing, reshaping how this asset...

Yahoo · Sep 26, 2026

Chugai Pharmaceutical And 2 Japanese AI Healthcare Stocks To Own

Japanese government bond yields have hit a 30‑year high, putting pressure on risk assets while pushing investors to look harder for growth themes with clear, real world use cases. Healthcare powered by artificial intelligence in Japan sits at the intersection of those needs and opportunities. This article introduces three AI focused healthcare stocks from our screener that investors may wish to evaluate as they consider that shift. The three stocks highlighted below are only a small sample of...

Yahoo · Sep 9, 2026

Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors

TOKYO, September 09, 2026--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been awarded the Lasker-DeBakey Clinical Medical Research Award, one of the world's most prestigious scientific honors.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By